Conference Correspondent

ASH 2020 - Multiple Myeloma

Preliminary results from a phase 2 study of isatuximab in patients with amyloid light-chain (AL) amyloidosis who were previously treated showed encouraging efficacy and a good safety profile. Read More ›

Consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance proved superior to lenalidomide maintenance alone in progression-free survival and myeloma response among transplant-eligible patients with NDMM. Read More ›

Although promising efficacy and acceptable toxicity were reported for belantamab mafodotin + pomalidomide + dexamethasone in patients with RRMM, the high rate of dose holds at the 2.5-mg/kg level warranted examination of alternative dosing schedules. Read More ›

Adding daratumumab to lenalidomide, bortezomib, and dexamethasone induction and consolidation, followed by maintenance with lenalidomide ± daratumumab for transplant-eligible patients with NDMM elicits deep and improving responses, with no additional safety concerns upon longer follow-up. Read More ›

Results from a first-in-human study of AMG 701, an anti-BCMA BiTE molecule, showed an acceptable safety profile, promising efficacy, and a favorable pharmacokinetic profile in heavily pretreated patients with RRMM, thereby supporting ongoing evaluation. Read More ›

Interim results from the STOMP study show that the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates and encouraging progression-free survival in heavily pretreated patients with multiple myeloma. Read More ›

Results from a phase 3 study of circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) + thalidomide and dexamethasone demonstrated this was a safe and effective treatment for patients with RRMM, including those with a poor prognosis. Read More ›

The IKEMA study interim analysis showed isatuximab + carfilzomib and dexamethasone resulted in a clinically meaningful improvement in depth of response, with more patients reaching minimal residual disease–negativity compared with carfilzomib and dexamethasone alone. Read More ›

The updated analysis of the phase 1 study of teclistamab in patients with RRMM shows favorable efficacy and manageable safety, and supports the planned phase 2 monotherapy trial at 1500 μg/kg administered subcutaneously. Read More ›

Results from a phase 1 study of talquetamab, a first-in-class bispecific antibody, show encouraging clinical activity with manageable toxicity in heavily pretreated patients with RRMM. The study is ongoing to identify a dose for phase 2 investigation. Read More ›

Page 1 of 3

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: